Pahang Pharmacy
Concise Prescribing Info
Cryptococcal meningitis & infections at other sites (eg, pulmonary, cutaneous). Maintenance therapy in prevention of cryptococcal meningitis relapse in AIDS patients. Candidemia, disseminated candidiasis & other invasive candidal infections. Mucosal candidiasis eg, oropharyngeal, esophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous & chronic oral atrophic candidiasis. Acute or recurrent vag candidiasis. Prevention of fungal infections in patients w/ malignancy predisposed to such infection as a result of cytotoxic chemo- or radiotherapy. Dermatomycosis eg, tinea pedis, corporis & cruris, pityriasis versicolor & candida infections.
Dosage/Direction for Use
Adult Cryptococcal meningitis & cryptococcal infections at other sites 400 mg on 1st day followed by 200-400 mg once daily for at least 6-8 wk. Prevention of cryptococcal meningitis relapse in AIDS patient 200 mg daily after receiving full course of primary therapy. Candidemia, disseminated candidiasis & other invasive candidal infections 400 mg on 1st day followed by 200 mg daily, may be increased to 400 mg daily. Oropharyngeal candidiasis 50-100 mg once daily for 7-14 days. Atrophic oral candidiasis associated w/ dentures 50 mg once daily for 14 days concurrently w/ local antiseptics. Other mucosal candidal infections (except vag candidiasis) 50 mg daily for 14-30 days, may be increased to 100 mg. Vag candidiasis 150 mg as single dose. Reduce incidence of recurrent vag candidiasis 150 mg once mthly from 4-12 mth. Prevention of candidiasis 50-400 mg once daily. Patient w/ high risk of systemic infection 400 mg once daily. Dermal infections eg, tinea pedis, corporis, cruris & candida infections 150 mg once wkly or 50 mg once daily for 2-4 wk. Tinea pedis Up to 6 wk. Tinea versicolor 300 mg once wkly for 2 wk or 300-400 mg single dose or 50 mg once daily for 2-4 wk.
May be taken with or without food.
Hypersensitivity to fluconazole or azole related compd. Concomitant use w/ terfenadine or cisapride.
Special Precautions
Monitor hepatic function & discontinue use if clinical signs or symptoms of hepatic disease develops. Discontinue use if rash, bullous lesions or erythema multiforme develops in patients w/ invasive/systemic fungal infections or treated for superficial fungal infection. Patients w/ potentially proarrhythmic conditions. QT interval prolongation. Co-administration w/ terfenadine. Renal impairment. Not recommended during pregnancy. Avoid use during lactation.
Adverse Reactions
Headache, dizziness, seizures, taste perversion; rash, alopecia, exfoliative skin disorders; GI disorders; hepatic toxicity; leukopenia; allergic reaction eg, anaphylaxis, urticaria; hypercholesterolaemia, hypertriglyceridaemia, hypokalaemia; QT prolongation, Torsade de pointes.
Drug Interactions
Increased prothrombin time w/ coumarin-type anticoagulants. Prolonged serum t½ w/ sulfonylureas eg, chlorpropamide, glibenclamide, glipizide & tolbutamide. Increased plasma conc w/ hydrochlorothiazide. Increased phenytoin plasma conc. Enhanced metabolism by rifampicin. Increased cyclosporin levels. Decreased theophylline clearance rate. Increased serum levels of rifabutin, tacrolimus, zidovudine, astemizole or other CYP450-metabolised drugs. Increased risk of ventricular arryhthmia w/ cisapride & pimozide. Prolonged QTc interval w/ terfenadine.
MIMS Class
ATC Classification
J02AC01 - fluconazole ; Belongs to the class of triazole derivatives. Used in the systemic treatment of mycotic infections.
Flucozol cap 150 mg
20 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in